SCHEMBL7188904

SCHEMBL7188904

CCN1CCCC1CNC(=O)Nc1nc2cc(OS(=O)(=O)c3ccc(-n4ccnc4)cc3)ccc2[nH]1.O=C(NCCN1CCCC1)Nc1nc2cc(OS(=O)(=O)c3ccc(-n4ccnc4)cc3)ccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.38
MET P08581 1/20 0.35
CDK9 P50750 1/20 0.35
DRD3 P35462 4/20 0.35
DRD2 P14416 3/20 0.35
HRH3 Q9Y5N1 2/20 0.35
THRB P10828 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
SLC6A4 P31645 1/20 0.35
HTR2B P41595 1/20 0.35
KCNH2 Q12809 1/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2D6 P10635 3/20 0.35
CA2 P00918 2/20 0.35
DRD1 P21728 2/20 0.35
DRD4 P21917 2/20 0.35
CA9 Q16790 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5033520 0.95 NAMPT (0.42) NAMPTMETCDK9DRD3DRD2
SCHEMBL5042872 0.90 MET (0.40) NAMPTMETCDK9DRD3DRD2
SCHEMBL5042894 0.89 MET (0.40) NAMPTMETCDK9DRD3DRD2
SCHEMBL5036703 0.86 DRD3 (0.42) METCDK9DRD3DRD2HRH3
SCHEMBL5040744 0.84 CYP1A2 (0.45) NAMPTMETCDK9DRD3MEN1
SCHEMBL5036073 0.83 DRD3 (0.44) NAMPTMETCDK9DRD3DRD2
SCHEMBL5042941 0.82 MET (0.44) NAMPTMETCDK9DRD3DRD2
SCHEMBL5037703 0.82 NAMPT (0.42) NAMPTMETCDK9DRD3DRD2
SCHEMBL5140307 0.81 MET (0.45) METCDK9DRD3MEN1KMT2A
SCHEMBL5035937 0.81 MET (0.43) METCDK9CYP2D6CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432417-A2 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER Aventis Pharma S.A. (FR) 2004-06-30 EP disclosed
WO-2003028721-A2 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER AVENTIS PHARMA S.A. (FR) 2003-04-10 WO disclosed